• When administered per orally at doses of 20 and 50 mg/kg, 1 reduced the serum uric acid level by 49.9 and 63.9%, respectively and 2 reduced the level by 31.2 and 44.4%, respectively. (biomedsearch.com)
  • On the other hand, when the same doses were given intraperitoneally, both of compounds also exhibited a dose-dependent and more marked reduction of the serum uric acid level (% reduction at 20 and 50 mg/kg were 63.0 and 95.1% in 1, respectively and 66.9 and 86.5% in 2, respectively). (biomedsearch.com)
  • Other outcomes were: serum uric acid level, blood pressure (diastolic and systolic), markers of inflammation (C-reactive protein levels), all-cause mortality, adverse events and serious adverse events. (biomedcentral.com)
  • Oxygen consumption, aconitase activity, and uric acid were evaluated in isolated mitochondria from renal cortex. (hindawi.com)
  • This condition is caused by overproduction of uric acid or impaired renal clearance. (ucdenver.edu)
  • Data obtained included serum uric acid, serum creatinine or other estimates of glomerular filtration rate, incidence of end-stage renal disease (ESRD), systolic and diastolic blood pressure, proteinuria, cardiovascular disease and adverse events. (biomedcentral.com)
  • Recent evidence suggests that uric acid (UA), regardless of crystal deposition, may play a direct pathogenic role in renal disease. (biomedcentral.com)
  • The investigators have reported a clear relationship between higher serum uric acid and increased intrarenal angiotensin II as assessed by intravenous angiotensin II (Ang II) infusions in human subjects.11 In this model, the change in renal blood flow in response to infused Ang II serves as an indirect indicator of renal vascular exposure to endogenous Ang II. (clinicaltrials.gov)
  • A cell-permeable, aromatic sulfonamide derivative with a hydroxamic acid group that potently inhibits mammalian HDAC by binding to the active site zinc. (163.com)
  • To determine the maximum tolerated dose, dose-limiting toxicities(DLTs), and pharmacokinetics of S-1, a combination of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and oxonic acid, administered once daily in patients with advanced cancer. (aacrjournals.org)
  • As a second-line chemotherapy for metastatic colorectal cancer, combination therapy with S-1 and irinotecan was shown to be non-inferior to a folinic acid, 5-FU and irinotecan (FOLFIRI) regime ( 6 ). (spandidos-publications.com)
  • Although uric acid (UA) can function as a systemic antioxidant, its pro-inflammatory properties have been postulated to play an important role in the pathogenesis of cancer. (springeropen.com)